Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type


REGENERON PHARM   FYE=12 (December)

Annual - Income Statement - Company Specific

Fiscal period2021202020192018201720162015201420132012
Period End Date12/31/202112/31/202012/31/201912/31/201812/31/201712/31/201612/31/201512/31/201412/31/201312/31/2012
Revenues: Net product sales12,117.205,567.604,834.404,106.203,718.503,338.402,689.481,750.761,425.84858.09
Revenues: Collaboration revenue: Bayer HealthCare1,409.301,186.101,145.601,036.10938.10744.30580.49495.56220.2970.10
Revenues: Collaboration revenue: Sanofi-aventis1,902.201,186.40403.60(125.70)877.20658.70758.87541.30430.11423.81
Revenues: Contract manufacturing--------------------
Revenues: Contract research and development--------------------
Revenues: Research progress payments--------------------
Revenues: Technology Licensing & Other Revenue281.20557.00174.00129.00338.40119.0074.8931.9428.5126.47
Revenues: Collaboration revenue: Roche361.80------------------
Total Revenues16,071.708,497.106,557.605,145.605,872.204,860.404,103.732,819.562,104.751,378.48
Cost of goods sold1,773.10491.90362.30180.00202.50194.60241.70129.03118.0583.93
Cost of collaboration manufacturing664.40628.00402.80237.50194.60105.10151.0175.9937.310.53
Gross Profit13,634.207,377.205,792.504,728.105,475.10--3,711.022,614.541,949.391,294.02
Research and development2,908.102,735.002,450.001,468.802,075.102,052.301,620.581,271.35859.95625.55
General and Administrative1,824.901,346.001,341.901,127.201,320.401,177.70838.53519.27346.39210.76
Other operating (income) expense, net45.60280.40209.20402.30------------
Total Operating Expense7,124.904,920.504,347.802,611.203,792.603,529.702,851.811,995.641,361.70920.76
Income (loss) from operations8,946.803,576.602,209.802,534.402,079.601,330.701,251.92823.92743.05457.71
Interest expense57.3056.9030.2028.2025.107.2014.2437.3746.4445.30
Earnings (Loss in) from Amgen-Regeneron Partners--------------------
Investment income----------------(0.23)2.01
Other contract income436.30290.70249.5047.3024.006.30(12.58)(25.31)----
Gain (Loss) on early extinguishment of debt--------------------
Other income (expense)379.00233.80219.3019.10(1.10)(0.90)(26.82)(62.68)(46.67)(43.29)
Pre-Tax Income9,325.803,810.402,429.102,553.502,078.501,329.801,225.10761.24696.38414.42
Income tax expense (benefit)1,250.50297.20313.30109.10880.00434.30589.04423.11282.64(335.85)
Current - Federal1,429.80199.00444.60223.70560.30787.00--------
Deferred - Federal(423.20)109.00(132.00)687.60317.10(377.40)--------
Current - foreign(38.40)21.40(2.60)20.604.80(1.40)--------
Current - State6.201.201.904.80(4.10)8.80--------
Deferred - foreign276.70(31.40)3.10(825.70)3.203.90--------
Deferred - state(0.60)(2.00)(1.70)(1.90)(1.30)13.40--------
Net income (loss) before cumulative effect of a change in accounting principle--------------------
Cumulative effect of adopting Statement of Financial Accounting Standards--------------------
Net income attributable to common shareholders8,075.303,513.202,115.802,444.401,198.50895.50636.06338.13413.74750.27
Continuing Operations- (Basic)--------------------
Cumulative effect of adopting--------------------
Net Earnings Per Share (Basic)76.4032.6519.3822.6511.278.556.173.364.237.92
Continuing Operations- (Diluted)--------------------
Cumulative effect of adopting SAB101--------------------
Net Earnings Per Share (Diluted)71.9730.5218.4621.2910.347.705.522.983.726.75
Weighted Average Shares Outstanding (Basic)105.70107.60109.20107.90106.30104.70103.06100.6197.9294.69
Weighted Average Shares Outstanding (Diluted)112.20115.10114.60114.80115.90116.30115.23113.41111.29115.38